SEARCH

SEARCH BY CITATION

References

  • Czirr E, Leuchtenberger S, Dorner-Ciossek C, Schneider A, Jucker M, Koo EH et al. (2007). Insensitivity to Abeta42-lowering nonsteroidal anti-inflammatory drugs and gamma-secretase inhibitors is common among aggressive presenilin-1 mutations. J Biol Chem 282: 2450424513.
  • De Strooper B (2010). Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol Rev 90: 465494.
  • Dovey HF, John V, Anderson JP, Chen LZ, Andrieu P, Fang LY et al. (2001). Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 76: 173181.
  • Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC et al. (2003). NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 112: 440449.
  • Fraering PC, Ye W, LaVoie MJ, Ostaszewski BL, Selkoe DJ, Wolfe MS (2005). Gamma-secretase substrate selectivity can be modulated directly via interaction with a nucleotide-binding site. J Biol Chem 280: 4198741996.
  • Gasparini L, Rusconi L, Xu H, del Soldato P, Ongini E (2004). Modulation of beta-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures. J Neurochem 88: 337348.
  • Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA et al. (2009). Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302: 25572564.
  • Hadland BK, Manley NR, Su D, Longmore GD, Moore CL, Wolfe MS et al. (2001). Gamma-secretase inhibitors repress thymocyte development. Proc Natl Acad Sci USA 98: 74877491.
  • Hardy J, Selkoe DJ (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353356.
  • Ho CY (2009). Preparation of biphenyl derivatives as γ-secretase modulators. WO2009052341A1. 2009 Apr 23.
  • Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S et al. (1996). Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274: 99102.
  • Imbimbo BP, Del Giudice E, Colavito D, D'Arrigo A, Dalle Carbonare M, Villetti G et al. (2007). 1-(3′,4′-Dichloro-2-fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J Pharmacol Exp Ther 323: 822830.
  • Imbimbo BP, Giardino L, Sivilia S, Giuliani A, Gusciglio M, Pietrini V et al. (2010). CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 20: 159173.
  • Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994). Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13: 4553.
  • Jerussi TP, Caubet JF, McCray JE, Handley DA (1998). Clinical endoscopic evaluation of the gastroduodenal tolerance to (R)- ketoprofen, (R)- flurbiprofen, racemic ketoprofen, and paracetamol: a randomized, single-blind, placebo-controlled trial. J Clin Pharmacol 38 (2 Suppl.): S19S24.
  • Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG (2001). Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21: 372381.
  • Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X et al. (2010). Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 67: 769780.
  • Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE et al. (2005). Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med 11: 545550.
  • Lewis HD, Beher D, Smith D, Hewson L, Cookson N, Reynolds DS et al. (2004). Novel aspects of accumulation dynamics and A beta composition in transgenic models of AD. Neurobiol Aging 25: 11751185.
  • Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B et al. (2000). Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20: 57095714.
  • McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, Yu C et al. (2005). Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47: 191199.
  • Mercken M, Brepoels E, De Jongh M, Laenen W, Raeymakers P, Geerts H (2000). Specific ELISA systems for the detection of endogenous human and rodent Aβ40 and Aβ42. Neurobiol Aging 21: S41.
  • Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gadient R et al. (2004). Modulation of notch processing by gamma-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 82: 341358.
  • Morihara T, Chu T, Ubeda O, Beech W, Cole GM (2002). Selective inhibition of Abeta42 production by NSAID R-enantiomers. J Neurochem 83: 10091012.
  • Page RM, Baumann K, Tomioka M, Perez-Revuelta BI, Fukumori A, Jacobsen H et al. (2008). Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation. J Biol Chem 283: 677683.
  • Peretto I, La Porta E (2008). Gamma-secretase modulation and its promise for Alzheimer's disease: a medicinal chemistry perspective. Curr Top Med Chem 8: 3846.
  • Pype S, Moechars D, Dillen L, Mercken M (2003). Characterization of amyloid beta peptides from brain extracts of transgenic mice overexpressing the London mutant of human amyloid precursor protein. J Neurochem 84: 602609.
  • Searfoss GH, Jordan WH, Calligaro DO, Galbreath EJ, Schirtzinger LM, Berridge BR et al. (2003). Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem 278: 4610746116.
  • Selkoe DJ (2004). Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med 140: 627638.
  • Singer SJ, Dewji NN (2006). Evidence that Perutz's double-beta-stranded subunit structure for beta-amyloids also applies to their channel-forming structures in membranes. Proc Natl Acad Sci USA 103: 15461550.
  • Stock N, Munoz B, Wrigley JD, Shearman MS, Beher D, Peachey J et al. (2006). The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent. Bioorg Med Chem Lett 16: 22192223.
  • Sung S, Yang H, Uryu K, Lee EB, Zhao L, Shineman D et al. (2004). Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease. Am J Pathol 165: 21972206.
  • Terai K, Iwai A, Kawabata S, Tasaki Y, Watanabe T, Miyata K et al. (2001). Beta-amyloid deposits in transgenic mice expressing human beta-amyloid precursor protein have the same characteristics as those in Alzheimer's disease. Neuroscience 104: 299310.
  • Watanabe H, Bernier F, Miyagawa T (2006). Therapeutic agent for Abeta related disorders. US20060241038A1. 2006 Oct 26.
  • Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU et al. (2001). A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414: 212216.
  • Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Golde TE, Koo EH (2003a). Abeta42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem 278: 3074830754.
  • Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A et al. (2003b). Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem 278: 3183131837.
  • Winkler E, Hobson S, Fukumori A, Dumpelfeld B, Luebbers T, Baumann K et al. (2009). Purification, pharmacological modulation, and biochemical characterization of interactors of endogenous human gamma-secretase. Biochemistry 48: 11831197.
  • Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T et al. (2004). Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 279: 1287612882.
  • Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL et al. (2003). Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23: 75047509.